Agency classClass IIOur severity:Severe FDA (Drugs)·D-1711-2015·Announced 2015-09-23

FDA Recalls Morphine and Ropivacaine Compounded Solution Due to Sterility Concerns

The Compounding Pharmacy of America is recalling a sterile morphine, ropivacaine, and baclofen solution because FDA inspections found GMP violations that may affect sterility.

The agency’s classification

FDA (Drugs): Class II

Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.

This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work

What this means for you

Our assessment, not the agency’s: severity 4/5 (Severe).

The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.

Our severity reasoning: The recall is classified as FDA Class II, and the hazard involves a lack of assurance of sterility in a compounded injectable solution, which carries a significant risk of serious injury or infection.

Plain-English summary

The Compounding Pharmacy of America is recalling Morphine 50 mg/ml + Ropivacaine 5 mg/ml + Baclofen 20 mcg/ml Solution, Sterile, Preservative Free. The product is a 33 ml solution distributed nationwide. The recall covers all lots distributed between November 2014 and May 2015, including lot 04072015@69 dated 7/6/2015.

The recall was initiated because an FDA inspection identified Good Manufacturing Practice (GMP) violations that potentially impact the product's quality and sterility. The lack of assurance of sterility poses a risk to patients using the medication.

Healthcare providers and patients should stop using the affected product immediately. Consumers should contact their healthcare provider for guidance on alternative treatments or further instructions.

The recalled product

Product: Morphine 50 mg/ml + Ropivacaine 5 mg/ml +Baclofen 20 mcg/ml Solution, Sterile, Preservative Free, The Compounding Pharmacy of America, Knoxville, TN
Manufacturer: The Compounding Pharmacy of America
Category: Drug — Compounded Injectable
Hazard: sterility
gmp-violation

Is your product affected?

Check your packaging against the codes below. If any of them match, the product is part of this recall.

Lot numbers (3)

All lots distributed between November 2014 and May 2015
04072015@69
7/6/2015

Distribution

Distributed nationwide across the United States.

Part of a larger recall action

This product is one of 382 recalled by The Compounding Pharmacy of America under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.

See all 382 products in this recall →

Same manufacturer · The Compounding Pharmacy of America

See all →

Critical
FDA Recalls Non-Sterile HCG and Methylcobalamin Injection Vials
FDA (Drugs) · 2018-02-21
Severe
Hydromorphone Solution Recalled Due to Sterility Assurance Concerns
FDA (Drugs) · 2015-09-23
Severe
Morphine and Bupivacaine Solution Recalled for Sterility Concerns
FDA (Drugs) · 2015-09-23
Severe
Methylcobalamin Injectable Recalled for Sterility Assurance Concerns
FDA (Drugs) · 2015-09-23
Severe
FDA Recalls Compounded Hydromorphone Fentanyl Bupivacaine Intrathecal Solution
FDA (Drugs) · 2015-09-23

Same hazard · sterility